Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Orthofix settles foreign bribery charges. Cardiosolutions wins $8 million investment for mitral valve technology. OraSure plans $75 million stock offering. More news in brief.

You may also be interested in...



Regulatory News In Brief

Federal and state regulatory news updates.

Judge Weighs $42 Million Orthofix Settlement With Feds

Orthofix pleaded guilty to the felony of obstructing a federal audit and also has settled civil charges with the federal government. But the settlement will not be final until it is approved by a federal judge, who postponed his decision last week.

OraSure Preps October Launch Of First-Ever In-Home HIV Test

Firm gains PMA approval for OraQuick July 3, making it the first available HIV test that can be performed entirely in the home by untrained users.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

See All
UsernamePublicRestriction

Register

MT031394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By